Edison issues flash note on ReNeuron Group (RENE)

LONDON, Jan. 24, 2019 (GLOBE NEWSWIRE) -- ReNeuron has announced the long-awaited dosing of the first patient in its placebo-controlled US Phase IIb (PISCES III) study in patients six to 12 months after ischemic stroke. The news has been well-received as it is rare for a small UK biotech to start dosing US patients with a novel stem cell-derived product.

PISCES III involves 110 patients, randomised 1:1 to either 20 million CTX0E03 cells or placebo at 40 clinical trial sites across the US. Further information on the study can be found at www.pisces3.org and this latest news continues ReNeuron’s run of positive newsflow in 2019, with the earlier announcement of a research collaboration on its exosome platform with a US-based biopharmaceutical company.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website www.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Andy Smith, +44 (0)20 3077 5700
healthcare@edisongroup.com